Security
Electra Therapeutics, Inc. Common stock · ETRA
ETRANASDAQCommon stockCurrentCIK 2088082Updated Nov 13, 2026
ETRA price & chart
Loading TradingView…
NASDAQ:ETRA on TradingView ↗About the company
We are a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. Our novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations, and increases upon activation to enable selective depletion of disease-driving cells while preserving normal immune function. By replacing broad immunosuppression with selective elimination of principal cells that drive disease, we believe our approach can do for immune-mediated diseases what precision oncology has done for cancer, transforming the treatment paradigm for patients. To our knowledge, we are the first company to advance this SIRP-targeted precision immune cell depletion approach into clinical development and demonstrate proof-of-concept in humans.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
SCHEDULE 13G - filed by Westlake BioPartners Fund I, L.P. regarding Electra Therapeutics, Inc.
SCHEDULE 13G - filed by Redmile Group, LLC regarding Electra Therapeutics, Inc.
SCHEDULE 13G - filed by LSP 7 Cooperatief U.A. regarding Electra Therapeutics, Inc.
SCHEDULE 13D - filed by ORBIMED ADVISORS LLC regarding Electra Therapeutics, Inc.
4 filing
Offerings
Registration 333-298617
- Gross proceeds
- 350000010.0
- Net proceeds
- 325500009.0
- Deal price
- 15.0
- Shares
- 23333334
- Offering price
- $15.00
- Ticker
- ETRA
Underwriters: Jefferies LLC, TD Securities LLC, Evercore Group L.L.C.
Registration 333-298997
Filing attachments
etra-ex99_1.htm · 8-K · 2026-11-12
Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027 Ipsoprubart Therapeutic Expansion Underway in Phase 1 Trial for T/NK Cell Malignancies, with Initial Data Expected in the Second Half of 2027 ELA822 Healthy Volunteer Data Expected in the First Half of 2027, with Patient Trial Initiation Plann…
Read attachment ↗tm2626160d1_ex99-1.htm · SCHEDULE 13G · 2026-09-28
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Electra Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Excha…
Read attachment ↗d61940dex107.htm · S-1/A · 2026-09-14
EX-10.7 8 d61940dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 E LECTRA T HERAPEUTICS, I NC. N ON -E MPLOYEE D IRECTOR C OMPENSATION P OLICY A DOPTED : A UGUST 19, 2026 E FFECTIVE D ATE : Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Electra Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Po…
Read attachment ↗d61940dex41.htm · S-1/A · 2026-09-14
EX-4.1 4 d61940dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Electra Therapeutics, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented h…
Read attachment ↗d61940dex107.htm · S-1 · 2026-08-28
EX-10.7 13 d61940dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 E LECTRA T HERAPEUTICS, I NC. N ON -E MPLOYEE D IRECTOR C OMPENSATION P OLICY A DOPTED : A UGUST 19, 2026 E FFECTIVE D ATE : Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Electra Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation P…
Read attachment ↗d61940dex42.htm · S-1 · 2026-08-28
EX-4.2 6 d61940dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 ELECTRA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT October 15, 2025 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of October 15, 2025, by and among ELECTRA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor” and collec…
Read attachment ↗